Cranial Nerve Enhancement in Multiple Sclerosis Is Associated With Younger Age at Onset and More Severe Disease

Lukas Haider¹,², Wei-Shin Evelyn Chan², Elisabeth Olbert³, Stephanie Mangesius⁴,⁵*, Assunta Dal-Bianco⁶, Fritz Leutmezer⁶, Daniela Prayer² and Majda Thurnher²

¹ NMR Research Unit, Department of Neuroinflammation, Faculty of Brain Science, Queen Square MS Centre, UCL Institute of Neurology, University College London, London, United Kingdom, ² Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria, ³ Department of Neurology, University Hospital Tulln, Tulln, Austria, ⁴ Department of Neuroradiology, Medical University of Innsbruck, AUT, Innsbruck, Austria, ⁵ Neuroimaging Core Facility, Medical University of Innsbruck, AUT, Innsbruck, Austria, ⁶ Department of Neurology, Medical University Vienna, Vienna, Austria

Background: The overall frequency of cranial nerve pathology, including cranial nerves other than the trigeminal nerve, as well as its relation to brainstem lesion formation on magnetic resonance imaging (MRI) and clinical correlates in multiple sclerosis (MS) is unknown.

Objective: We aimed to determine the frequency of cranial nerve enhancement on MRI, and its association with brainstem lesion formation and clinical outcomes.

Methods: We retrospectively analyzed, in 183 patients, (RRMS: 156, SPMS: 15, PPMS: 6, CIS: 6) 651 MRIs (76.5% on the identical scanner Siemens Trio Tim, 3T with identical MRI protocols). Frequencies of cranial nerve enhancement on post contrast T1-weighted MRIs were compared to lesion counts and the MS-severity-score.

Results: Cranial nerve enhancement was present in 8.2% of the analyzed MS patients (oculomotor-nerve: 1.1%, trigeminal-nerve: 2.7%, abducens-nerve: 2.2%, facial-/vestibulocochlear nerve: 1.6%, vagal-nerve: 0.5%). Of those, 13% suffered from repeated episodes and 27% exhibited a cranial nerve enhancement duration of >12 months. Age at MS onset was lower in patients with cranial nerve enhancement, 23 vs. 28 years, \( p = 0.049 \). The MS-severity-score, 5.15 vs. 0.88 (\( p = 0.019 \)), the T2 brainstem-, 1 vs. 0 (\( p = 0.041 \)), and the total intracranial contrast-enhancing lesion counts, 2 vs. 0 (\( p = 0.000 \)), were higher in patients with cranial nerve enhancement, compared to age-, disease duration-, and gender- matched MS patients.

Conclusions: Cranial nerve enhancement, present in 8.2% of our patients, was associated with a younger age at MS onset, brainstem lesions, and a more severe disease course.

Keywords: multiple sclerosis, magnetic resonance imaging, contrast media, cranial nerves, brain stem, retrograde neurodegeneration
INTRODUCTION

Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) (1). Isolated cranial nerve (CN) involvement was clinically reported in 10.4% (50/483) of all MS patients observed during a 5-year period, with 7.3% of those in whom CN involvement was a presenting symptom of MS, and, in 3.1%, as a sign of disease relapse (2). The oculomotor nerve was found to be clinically affected in 2%, the trigeminal nerve in 23%, the abducens nerve in 5%, the facial nerve in 18% and the vestibulocochlear nerve in 2% (2). This is in contrast to magnetic resonance imaging (MRI) studies, where systematically assessed data has thus far reported involvement of the trigeminal nerve only. On post contrast T1-weighted MRI, 2.8% (24/851) of MS patients exhibited enhancement of the cisternal portion of the trigeminal nerve at 0.5–1.5 Tesla (T) (3) and 2.9% (8/275) of patients at 1.0 T (4). By using 3D T2 turbo spin echo, 3D T2 fluid attenuated inversion recovery and 3D T1 inversion recovery and up to 0.5 mm in-plane resolution at 3 T, 23% (11/47) of patients displayed signal abnormalities in the central trigeminal pathways, including the root entry zone and either the trans-cisternal nerve or pontine nucleus (5). The possibility to visualize cisternal or central involvement of other (smaller) cranial nerves on MRI examinations has been reported in three case reports (6–8). Uzawa et al. reported an abducens palsy and facial nerve palsy due to a facial collicular plaque (6). Two cases were reported with clinical and radiological oculomotor nerve involvement in association with cerebral peduncular lesions close to the emergence of the third nerve and continuity of the enhancement between the demyelinated lesion and the cisternal portion of the third nerve (7, 8). While detection of cranial nerve enhancement (CNE) in cranial nerves other than the trigeminal nerve on 3T MRI performed for clinical purposes, is indicated, its frequency and its relation to brainstem lesion formation and clinical parameters is remains unknown. In this retrospective study, we therefore aimed to determine: (a) the frequency of cranial nerve enhancement (CNE) in randomly selected MS patients; (b) the dynamic on follow-up examinations; and (c) its correlation with disease severity and age at onset.

MATERIALS AND METHODS

Study Design

We selected 183 MS patients between 2002 and 2017 through our hospital information system (SAP SE) using the following selection criteria: (a) data entry via the MS-Neurology-Outpatient-Department; and (b) availability of more than one brain MRI. From a total of 838 MRI examinations 120 were excluded due to lack of pre- and post-contrast T1-weighted images (WI), 58 MRI examinations were excluded due to image artifacts (e.g., patient motion-related), or low resolution. A total of 651 MRI exams in 183 patients were included in the study (Table 1). A median of three MRI examinations (2–4) were analyzed per patient. The median time interval between baseline and follow-up MRIs was 834 days (336–1,850 days; 25–75 percentile range). There were 234 MRI examinations (36%) performed on a 1.5 T MRI clinical scanner, and 417 (64%) on a 3.0 T clinical scanner (Siemens Trio Tim).

Participants

We included individuals with the diagnosis of clinically definite multiple sclerosis according to the McDonald criteria (9) (RRMS: 156, SPMS: 15, PPMS: 6) and 6 individuals with the diagnosis of clinically isolated syndrome. The clinical data assessed included date of birth, gender, disease onset, disease course, Expanded Disability Status Scale (EDSS), and cranial nerve involvement (Table 2). The MS severity score (MSSS) was calculated according to Roysdogh et al. (10). Lumbar puncture was routinely performed in all MS patients in the course of the initial diagnostic process to rule out infectious diseases, especially viral or borrelia-induced neuritis. We did not collect data on MS specific treatments. The clinical annotations were derived from retrospective review of clinical routine charts.

Subgroup Selection

Two randomly selected groups of MS patients without CNE were matched for both gender and disease course. One group was also

### TABLE 1

| Disease type | Age (at MS onset) | Age (at BL MRI) | Age (at last MRI) | Female/male |
|--------------|------------------|----------------|------------------|-------------|
| CIS          | 31 (27–39)       | 30 (27–37)     | 31.5 (28–38)     | 6/0         |
| RRMS         | 27 (20–36)       | 32 (22–39)     | 34 (26.5–43)     | 104/52      |
| SPMS         | 31.5 (23–42)     | 46 (41–51)     | 49 (44–58)       | 11/4        |
| PPMS         | 31 (28–33)       | 35 (32–38)     | 43 (35–44)       | 3/3         |

Gender, age, age at MRI and disease duration were available for the entire cohort.
age-matched \((n = 15)\), whereas the other group was matched for age at disease onset \((n = 15)\).

### Image Acquisition

There were 76.5\% \((319/417)\) examinations performed on a clinical Siemens Trio Tim scanner \((3T)\) with a TR (repetition time) of 1800 ms, a TE (time to echo) of 2.19–3.79 ms, a TI (inversion recovery) of 900–1,100 ms, a matrix of 192 \(\times\) 192–484 \(\times\) 484, and a slice thickness of 1 mm \((Supplementary Table 1)\). The contrast agents Gadobutrol and Gadoteric acid were intravenously applied at a dose of 0.1–0.2 ml/kg. Due to the retrospective design we could not control for the time intervals from injection to post-contrast MRI. Scans from other MRI machines, including 1.5 T were included in the initial analysis, however, they did not contribute to the total number of cranial nerves with enhancement, which was only measured on 3T scans \(\text{(see section Results}. \text{We allowed for change between MRI scanners, e.g., baseline at 3T, FU-1 at 1.5, FU-2 at 3T).}

### Image Analysis

CN enhancement on post-contrast T1-(WI) in the cisternal segment was determined by consensus rating performed by three trained readers \(\text{(WSEC, TZ, and LH)}. \text{In the case of disagreement, expert rating was considered \(\text{(MT)}. \text{The optic nerve was excluded from the analysis because of its diencephalic origin and oligodendrocyte myelination. Cases of suspected CNE based on this initial review were subsequently subjected to region-of-interest (ROI)-based manual measurement of the CN signal intensity \(\text{(SI)}\) on pre- and post-contrast T1 WI with IMPAX EE R20 XV SU3, AGFA Healthcare, Mortsel, Belgium using multilplanar and curved reconstructions along the course of the cranial nerve. Therefore, a freehand ROI was drawn around each CN with suspected enhancement, using similar distances between the cerebrospinal fluid \(\text{(CSF)}\) and the CN in its cisternal segment on pre- and post-contrast T1 WI. Each SI was normalized by the SI of the CSF in the lateral ventricles of the same MR sequence. The ratio between the CSF-normalized CN-SIs on pre- and post-contrast images was calculated. CNs with an increase of signal intensity >110% was ultimately rated as positive. In these MS patients, the SI of the affected CN was also measured in the same manner in a second, negatively rated MR scan \(\text{(Supplementary Figure 1)}\) to prove the absence of an SI increase in negatively rated MRI scans. In two of all the cases with CNE, the affected CN was rated positively in all available MR scans.

Brainstem lesion load was manually counted on T2-weighted images \((T2-WI). \text{The total number of intracranial-enhancing lesions was determined on post-contrast T1-weighted images.}

### Statistical Analysis

The descriptive statistical analyses were performed using IBM SPSS Statistics 21 \(\text{(IBM, Armonk, NY, USA). Categorical}

### TABLE 3

| Pat. No. | CN involved | Side of CNE | Duration of CNE | REZ involvement on T2 | Lesion counts | Number of analyzed MRIs | MRI Follow-up [months] |
|----------|-------------|-------------|-----------------|-----------------------|---------------|-------------------------|------------------------|
| 12       | III         | Bilateral   | NDA             | No                    | 1             | 1                       | 2                      |
| 14       | III         | Left        | NDA             | Yes                   | 1             | 2                       | 2                      |
| 2        | V           | Bilateral   | >5 months       | Right: yes, left: no  | 1             | 5                       | 2                      |
| 7        | V           | Left>right  | <98 days        | Left: yes             | 2             | 19                      | 4                      |
| 8        | V           | Left>right  | >20 months      | No                    | 0             | 0                       | 4                      |
| 11       | V           | Left        | <11 months      | No                    | 1             | 0                       | 2                      |
| 15       | V           | Left        | >15 months      | No                    | 0             | 1                       | 2                      |
| 3        | VI          | Bilateral   | NDA             | No                    | 1             | 1                       | 2                      |
| 6        | VI          | Left>right  | >21 months      | No                    | 2             | 3                       | 4                      |
| 10       | VI          | Left        | 1st: <12 months; 2nd: <22 months | No | 0 | 2 | 10 | 102.1 |
| 13       | VI          | Right       | >13 months      | No                    | 0             | 3                       | 3                      |
| 1        | VII/VIII    | Left        | 1st: <18 months; 2nd: <12 months | Yes | 3 | 20 | 16 | 106.4 |
| 5        | VII/VIII    | Left        | <20 months      | No                    | 0             | 0                       | 2                      |
| 9        | VII/VIII    | Right       | NDA             | No                    | 1             | 5                       | 2                      |
| 4        | X           | Right       | NDA             | Yes                   | 4             | 7                       | 3                      |

CNE was bilateral in 20\% \((3/15)\), left-sided in 40\% \((6/15)\), right-sided in 20\% \((3/15)\), and bilateral but left-dominated in 20\% \((3/15)\). Estimations for the duration of CNE were not available for 33\% \((5/15)\) because CNE was present only in the last available MRI scan in these individuals. A CNE duration of >5 months was present in 7\% \((1/15)\), and a duration of >12 months in 27\% \((4/15)\). Patient No. 10 and No. 1 displayed two episodes of CNE on follow-up MRI. In patients with CNE, MS plaques near the root entry zone \(\text{(REZ)}\) of the affected CN were depicted on T2 or FLAIR images in 33\% \((5/15)\) of MS patients. In patients with CNE, a median of one lesion \(\text{(0–2)}\) was detected in the brainstem \(\text{(mesencephalon, pons, and medulla oblongata)}\) and two \(\text{(1–5)}\) contrast-enhancing lesions \(\text{(CEL)}\) in the total neurocranium. In patients with CNE, two MRIs were analyzed in 53\% \((8/15)\), three MRIs in 13\% \((2/15)\), four MRIs in 20\% \((3/15)\), ten MRIs and 16 MRIs each in 7\% \((1/15)\). The median follow-up period for individuals with CNE spanned 19.8 months \((10.8–102.1)\).
variables are presented as number (percentage), numerical variables are shown as median (25–75 percentile range). Group differences were calculated using the Mann–Whitney U-test.

RESULTS

Overall, cranial nerve enhancement (CNE) was present in 8.2% (15/183) of the analyzed MS patients. Trigeminal nerve enhancement was detected in 2.7% (5/183), oculomotor nerve enhancement was present in 1.1% (2/183), abducens nerve enhancement in 2.2% (4/183), vestibulocochlear or facial nerve enhancement in 1.6% (3/183), and vagus nerve enhancement in 0.5% (1/183) (Table 3). No contrast enhancement was observed in olfactory, trochlear, glossopharyngeal, accessory, or hypoglossal nerves. CNE was bilateral in 20% (3/15), left-sided in 40% (6/15), right-sided in 20% (3/15), and bilateral but left-dominated in 20% (3/15) (Table 3, Figures 1A,C). CNE was found either proximally (Figures 2B,D, when compared to the pre-contrast images, Figures 2A,C), distally, or along the entire cisternal segment of the CN (Figures 1A,C).

Estimations for the duration of CNE were not available for 33% (5/15) because CNE was present only in the last available MRI scan in these individuals. Although CNE was found to be a temporarily limited finding in 7% (1/15) (Figures 1C,D), it lasted for >5 months in 7% (1/15) and >12 months in 27% (4/15) (Table 3 and Figure 3). Patients No. 10 and No. 1 displayed two episodes of CNE on follow-up MRIs.

T2 lesions with extension to the proximity of the root entry/exit zone (REZ) were detected in 33% (5/15) of MS patients (Figures 1A,B, white asterisk). Contrast enhancement of such REZ lesions showed continuous extension into the enhancing CN (Figure 1A white asterisk). In one of these five patients the MS lesion in the REZ preceded the CNE (by 18 days). We did not observe a case were CNE preceded REZ lesion formation. Overall, patients with CNE had a median of one T2 lesion (0–2) in the brainstem and two contrast-enhancing lesions (CEL) (1–5) in the total neurocranium (Table 3). Two randomly selected groups of MS patients without CNE were matched for both gender and disease course. One group was also age-matched, whereas the other group was matched for age at disease onset. Compared to patients with CNE, there was a significant lower frequency of T2 brainstem lesions \( n = 0 \) (0–0); \( p = 0.041 \) in age-matched MS patients. This difference in T2 brainstem lesions was lost when patients were matched for age at disease onset \( [n = 1 \ (0–1), \ p = 0.267] \) (Supplementary Table 2). CEL counts were
Cranial nerve enhancement (CNE) was present in 8.2% (15/183) of our randomly selected MS patients, with a median of three scans/patient (in total, 651 scans) analyzed at a median follow-up interval of 19.8 months. The optic nerve was excluded from the analysis because of its diencephalic origin and oligodendrocyte myelination (11). Due to the small diameter of the cranial nerves, other than the fifth nerve, the contrast enhancement is challenging to detect and multiplanar reconstructions are helpful. Oculomotor nerve enhancement was present in 1.1% (2/183), trigeminal nerve enhancement in 2.7% (5/183), abducens nerve enhancement in 2.2% (4/183), vestibulocochlear or facial nerve enhancement in 1.6% (3/183), and vagus nerve enhancement in 0.5% (1/183) (Table 3). While involvement of CNs other than the trigeminal nerve has been reported by only three case reports—one on the abducens nerve (6) and two on the oculomotor nerve (7, 8)—similar frequencies of peripheral trigeminal nerve involvement on MRI have been reported previously (2.8–2.9%), despite only one scan per patient analyzed at 0.5–1.5 T (3, 4).

This might be explained by recurrent CNE, which was found in 13% (2/15), by long-lasting CNE of >5 months in 7% (1/15) and by CNE >12 months, present in 27% (4/15), despite exclusion of so-called "normal facial nerve enhancement" (12). To our knowledge, we provide the first systematic description of longitudinal changes of CNE (Table 3 and Figure 3). Anterograde trans-synaptic degeneration has been established as a mechanism to explain optic neuritis related white matter abnormalities in the optic radiation in MS (13). In this model, changes in the posterior visual pathways relate to primary optic nerve defects in the connected tract system (14). Glial activation and demyelination in the posterior visual pathways precede the appearance of disrupted axonal transport (14). We hypothesize, that CNE, as phenomenologically observed in our study (15), might be a consequence of such tract-related myelin disintegration in the course of ante/retrograde/ trans-synaptic neurodegeneration (16, 17). In the setting of multiple sclerosis it would follow both white matter lesions (18) and diffuse axonal injury (19). Due to the nature of MS lesion...
FIGURE 3 | (A,C,E) (Patient No. 8): Pre-contrast and corresponding post contrast T1-weighted axial images (B,D,F) reveal long-lasting bilateral (left-dominated) trigeminal enhancement (white arrows) of >20 months on three follow-up MRIs (A,B: 14.08.2015; C,D: 19.04.2016; E,F: 09.05.2017). No brainstem lesion was detected in this case on T2-weighted images (not shown).

TABLE 4 | A clinical record compatible with CN involvement was found in 33% (5/15) by retrospective review of routine neurological examinations.

| Pat. No. | CN involved | Clinical record of CNE | Disease type | M/F | Age at MS onset [years] | Disease duration at incidence of CNE [days] | MS severity score (MSSS) |
|----------|-------------|------------------------|--------------|-----|------------------------|------------------------------------------|------------------------|
| 12       | III         | No                     | RRMS         | F   | 20                     | 327                                      | 2.44                   |
| 14       | III         | Yes                    | RRMS         | M   | 29                     | 72                                       | 0.67                   |
| 2        | V           | No                     | RRMS         | M   | 42                     | 1                                        | 9.88                   |
| 7        | V           | No                     | RRMS         | M   | 14                     | 804                                      | 0.35                   |
| 8        | V           | No                     | RRMS -> SPMS | F   | 19                     | 8,469                                    | 7.38                   |
| 11       | V           | Yes                    | RRMS         | F   | 23                     | 6,138                                    | 1.89                   |
| 15       | V           | No                     | RRMS         | M   | 15                     | 3,970                                    | 4.94                   |
| 3        | VI          | No                     | RRMS         | M   | 14                     | 3,276                                    | 0.21                   |
| 6        | VI          | No                     | CIS -> RRMS | F   | 38                     | 1                                        | 6.0                    |
| 10       | VI          | No                     | RRMS -> SPMS | M   | 27                     | 4,917                                    | 2.34                   |
| 13       | VI          | No                     | RRMS         | M   | 20                     | 7,526                                    | 5.15                   |
| 1        | VII/VIII    | Yes                    | RRMS         | M   | 13                     | 66                                       | 6.14                   |
| 5        | VII/VIII    | Yes                    | RRMS         | M   | 30                     | 1,552                                    | 5.79                   |
| 9        | VII/VIII    | No                     | RRMS         | M   | 28                     | 39                                       | 5.41                   |
| 4        | X           | Yes                    | RRMS         | M   | 24                     | 2,388                                    | 9.33                   |

Between the first and last MRI, 7% (1/15) changed from clinically isolated syndrome (CIS) to relapsing remitting MS (RRMS) and 13% (2/15) changed from RRMS to secondary progressive MS (SPMS); all other cases remained RRMS. The female/male ratio was 8/7. There were 27% (4/15) who had a juvenile disease onset before the age of 18. The median age of MS-onset was 23 (15–29). In 40% (6/15), CNE presented within the first year after disease onset, and 13% (2/15) had CNE on their initial MRI at disease start. Patients with CNE had a median MS severity score (MSSS) of 5.15 (1.89–6.14) (25–75% range). Patient No. 2 suffered from intravenous drug abuse; Patient No. 1 presented with a juvenile Marburg-type MS.
revealed significantly more \[n = 1 (0–2)\] T2 brainstem lesions than patients matched for age, gender, disease duration, and disease course \[n = 0 (0–0); p = 0.041\]. This difference was lost when patients were matched for age at MS onset \[n = 1 (0–1); p = 0.267\] (Table 3 and Supplementary Table 2). Although glossopharyngeal neuralgia has been described as a rare finding in MS (20), and vocal cord paralysis is rare in patients with MS (21–23), patient No. 4 represents, to our knowledge, the first reported case suggestive of a brainstem lesion associated with vagus nerve involvement in MS. This patient presented with a newly detected, subtle right-sided cisternal enhancement of the vagal nerve and a non-enhancing lesion in its REZ (Supplementary Figure 2). Contralateral uvular deviation and ipsilateral palatal drop were noted in a clinical examination, performed 6 days after the MR exam, which was clinically compatible with involvement of the right vagal nerve (Table 3).

A possible clinical correlate for CNE was present in 33% (5/15) at the time of, or after CNE, affecting the oculomotor, trigeminal, facial/vestibulocochlear, and vagal nerves (Table 4). The clinical annotations were derived from a retrospective review of clinical routine charts. The examination of cranial nerves is a standard part of the clinical routine examination. Although the routine setting might lower our sensitivity to detect a clinical correlate of CNE (e.g., due to different clinical raters), it is unlikely to increase it.

While the significant predominance of secondary progressive multiple sclerosis (SPMS) cases in patients with trigeminal enhancement has been reported (4), this finding was not present in our cohort \(p > 0.5\) (Table 4). CNE manifested in 40% (6/15) within the first year after disease onset (Table 4). In patients with CNE enhancement, 27% (4/15) had a juvenile disease onset before the age of 18 years and the median age in this group of 23 years (15–29 years) was significantly lower than the median age of patients without CNE at 28 years of age (22–36 years), \(p = 0.049\). Patients with pediatric-onset MS have been previously reported to suffer from more and larger T2 lesions than adults on baseline and follow-up MRIs (24), and a higher frequency of brainstem attacks (25). In line with these findings, patients with CNE revealed more brainstem lesions [median 1 (0–2)] and higher MSSS \([5.15 (1.89–6.14)]\) than age-matched MS patients \([0(0–0); p = 0.41 and 0.88 (0.35–3.19); p = 0.019\), respectively], despite the inherent limitations of retrospective study design and small sample size.

CNE of the fifth cranial nerve has been reported previously at 1.5T at a frequency of 2.8% (4) and we therefore included 36% (234/651) of 1.5T scans in our analysis. However, all patients with CNE in our study, 8.2% (15/183), were detected on 3T MRI, suggesting an increase in the detection rate with higher field strength. In 76.5% (319/417) of all cases analyzed on 3T images, MR protocol parameters were standardized (Supplementary Table 1). Due to the retrospective study design, we could not control for potentially important factors, known to influence contrast enhancement on MRI, such as the timespan between contrast application and image acquisition and the exact T1 sequence parameters and gadolinium concentration/patient for all scans. Additionally, patients in a tertiary MS center might more often be in an active inflammatory stage of disease and receive MRIs more frequently than patients with long or benign disease courses (26). We could not control the MS relapse to MRI intervals and MS treatments prior to MRI. We, therefore, suggest that our data on CNE cannot be generalized to an overall CNE prevalence in MS, but rather reflect a scanner-, MRI protocol-, and detection threshold-dependent prevalence of CNE, in a cohort that is routinely imaged in an outpatient department setting. Clinical annotation was derived from retrospective chart review. These data were not recorded in a standardized fashion and, thus, could not generate a standardized, quantitative, comprehensive dataset.

This study is further limited by the lack of a control/reference tissue, which is not available from a biological point of view and the lack of a control patient cohort, which is not available due to restrictive and indication determined use of contrast agents in our department. The analysis was further restricted to a homogenous MS cohort and does not include other chronic CNS conditions, such as Neuromyelitis Optica Spectrum Disorders (NMOSD).

Taken together, our data indicate neurodegeneration via brainstem lesion formation as a potential source for CNE. The qualitative and quantitative detection threshold of CNE by MRI is reached more easily at higher field strengths, in patients with more aggressive MS disease courses and higher brainstem lesion loads. Tailored MR protocols and dedicated image analysis might significantly increase visualization of clinically relevant and potentially underestimated cranial nerve enhancement in patients with multiple sclerosis.

DATA AVAILABILITY STATEMENT

The datasets for this manuscript are not publicly available because data privacy can not be ensured due to potential facial recognition on the cranial MRIs used for this study. Requests regarding data access should be directed to: LH, lukas.haider@meduniwien.ac.at; MT, majda.thurnher@meduniwien.ac.at.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by 1464/2017. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

LH, W-SC, EO, SM, AD-B, FL, DP, and MT contributed to the study design, data acquisition, data analysis, data interpretation, manuscript drafting, and approved the final version.

FUNDING

LH was supported by the European Society of Neuroradiology (ESNR) Research Fellow Ship and the ECTRIMS/MAGNIMS Research Fellow Ship. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
ACKNOWLEDGMENTS

We thank Tobias Zrzavy, MD, Ph.D. for MRI consensus rating and Prof. G. Kasprian, MD, Ph.D. for valuable expert feedback on MRI analysis.

REFERENCES

1. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. (2015) 14:183–93. doi: 10.1016/S1474-4422(14)70256-X

2. Zadro I, Barun B, Habek M, Brinar V. Isolated cranial nerve palsies in multiple sclerosis. Clin Neurol Neurosurg. (2008) 110:886–8. doi: 10.1016/j.clineuro.2008.02.009

3. van der Meij AH, Tan IL, Barkhof F. Incidence of enhancement of the trigeminal nerve on MRI in patients with multiple sclerosis. Mult Scler. (2002) 8:64–7. doi: 10.1191/1352458502ms7750a

4. da Silva CJ, da Rocha AJ, Mendes MF, Maia AC Jr, Braga FT, Tilbery CP. Trigeminal involvement in multiple sclerosis: magnetic resonance imaging findings with clinical correlation in a series of patients. Mult Scler. (2005) 11:282–5. doi: 10.1191/1352458505ms11860a

5. Mills RJ, Young CA, Smith ET. Central trigeminal involvement in multiple sclerosis using high-resolution MRI at 3 T. Br J Radiol. (2010) 83:493–8. doi: 10.1259/bjr/05228893

6. Uzawa A, Mori M, Ito S, Kuwabara S. Neurological picture, disability and facial nerve palsies due to a facial collicular plaque in multiple sclerosis. J Neurol Neurosurg Psychiatry. (2011) 82:85–6. doi: 10.1136/jnp.2010.206870

7. Bhatti MT, Schmalfuss IM, Williams IS, Quisling RG. Peripheral third cranial nerve enhancement in multiple sclerosis. Am J Neuroradiol. (2003) 24:1390–5.

8. Bor N, Amador MD, Dormont D, Lubetzki C, Bertrand A. Involvement of peripheral III nerve in multiple sclerosis patient: report of a new case and discussion of the underlying mechanism. Mult Scler. (2017) 23:748–50. doi: 10.1177/1352458516687401

9. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. (2018) 17:162–73. doi: 10.1016/S1474-4422(17)30470-2

10. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawyer SJ, Vukusic S, et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology. (2005) 64:1144–51. doi: 10.1221/01.WNL.0000156155.19270.F8

11. Fuhrmann S. Eye morphogenesis and patterning of the optic vesicle. Curr Topics Dev Biol. (2010) 93:61–84. doi: 10.1016/B978-0-12-385044-7.00003-5

12. Martín-Duverneuil N, Sola-Martínez MT, Maux Y, Cognard C, Weil A, Mompount D, et al. Contrast enhancement of the facial nerve on MRI: normal or pathological? Neuroradiology. (1997) 39:207–12. doi: 10.1007/s002340050395

13. Tur C, Goodkin O, Altmann DR, Jenkins TM, Miskiel K, Mirigliani A, et al. Longitudinal evidence for anontograde trans-synaptic degeneration after optic neuritis. Brain. (2016) 139(Pt 3):816–28. doi: 10.1093/brain/awv396

14. You Y, Joseph C, Wang C, Gupta V, Liu S, Yiannikas C, et al. Demyelination precedes axonal loss in the transneuronal spread of human neurodegenerative disease. Brain. (2019) 142:426–42. doi: 10.1093/brain/awy338

15. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain. (1990) 113(Pt 5):1477–89. doi: 10.1093/brain/113.5.1477

16. Waller A. Experiments on the section of the glossopharyngeal and hypoglossal nerves of the frog, and observations of the alterations produced thereby in the structure of their primitive fibres. Philos Trans R Soc London. (1850) 140:423–29. doi: 10.1098/rsld.1850.0021

17. Chaudhry V, Glass JD, Griffin JW. Wallerian degeneration in peripheral nerve disease. Neurol Clin. (1992) 10:613–27. doi: 10.1016/0703-8619(92)30200-7

18. Kolasideki J, Stagg CJ, Chance SA, Deluca GC, Easri MM, Chang EH, et al. A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain. (2012) 135(Pt 10):2938–51. doi: 10.1093/brain/aws242

19. Haider L, Simonidou C, Steinberger G, Hametner S, Grigoriadis N, Dereti G, et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry. (2014) 85:1386–95. doi: 10.1136/jnnp-2014-307712

20. Carriere PR, Montella S, Petracca M. Glossopharyngeal neuralgia as onset of multiple sclerosis. Clin J Pain. (2009) 25:737–9. doi: 10.1097/AJP.0b013e3181f33b

21. Holinger LD, Holinger PC, Holinger PH. Etiology of bilateral abductor vocal cord paralysis: a review of 389 cases. Ann Otol Rhinol Laryngol. (1976) 85(4 Pt 1):428–36. doi: 10.1177/000348497608500402

22. Urquhart AC, St. Louis EK. Idiopathic vocal cord palsies and associated neurological conditions. Arch Otolaryngol. (2005) 131:1081–92. doi: 10.1001/archotol.131.12.1086

23. Rontal E, Rontal M, Wald J, Rontal D. Botulinum toxin injection in the treatment of vocal fold paralysis associated with multiple sclerosis: a case report. J Voice. (1999) 13:274–9. doi: 10.1016/S0892-1997(99)80033-0

24. Waubant E, Chabas D, Okuda DT, Glenn O, Mowry E, Henry RG, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. (2009) 66:967–71. doi: 10.1001/archneurol.2009.135

25. Waldman A, Ness J, Pohl D, Simone IL, Anlar B, Amato MP, et al. Pediatric multiple sclerosis: clinical features and outcome. Neurology. (2016) 87(9 Suppl. 2):S74–81. doi: 10.1212/WNL.0000000000003028

26. Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. (2018) 378:169–80. doi: 10.1056/NEJMr1401483

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Haider, Chan, Olbert, Mangesius, Dal-Bianco, Leutmezer, Prayer and Thurnder. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2019.01085/full#supplementary-material